Sep 7, 2023 Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
Sep 6, 2023 Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights
Aug 8, 2023 Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs
Aug 4, 2023 Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference
Aug 4, 2023 Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Jun 22, 2023 Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision Promise<sup>SM</sup> Pivotal Phase 3 Platform Trial
Jun 5, 2023 Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
